1. Home
  2. SOWG vs CING Comparison

SOWG vs CING Comparison

Compare SOWG & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

HOLD

Current Price

$3.23

Market Cap

69.9M

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$5.06

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOWG
CING
Founded
2010
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.9M
64.5M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
SOWG
CING
Price
$3.23
$5.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
14.9K
132.7K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
56.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$3.16
52 Week High
$4.45
$11.89

Technical Indicators

Market Signals
Indicator
SOWG
CING
Relative Strength Index (RSI) 47.29 49.11
Support Level $2.45 $5.08
Resistance Level $3.65 $5.20
Average True Range (ATR) 0.27 0.30
MACD -0.01 -0.04
Stochastic Oscillator 5.28 15.22

Price Performance

Historical Comparison
SOWG
CING

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: